Christopher B Umbricht

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3349906/publications.pdf

Version: 2024-02-01

394421 330143 37 1,856 19 37 citations h-index g-index papers 39 39 39 3443 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Hypermethylation of 14-3-3 $\dagger f$ (stratifin) is an early event in breast cancer. Oncogene, 2001, 20, 3348-3353.	5.9	284
2	Modeling precision treatment of breast cancer. Genome Biology, 2013, 14, R110.	9.6	264
3	Integrated Genomic Analysis of $\tilde{HA}^{1/4}$ rthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell, 2018, 34, 256-270.e5.	16.8	195
4	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research, 2014, 74, 2160-2170.	0.9	149
5	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. Journal of Clinical Oncology, 2017, 35, 751-758.	1.6	110
6	DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biology and Therapy, 2010, 10, 44-53.	3.4	85
7	Identification of Genes Differentially Expressed in Benign versus Malignant Thyroid Tumors. Clinical Cancer Research, 2008, 14, 3327-3337.	7.0	77
8	MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review. Thyroid, 2015, 25, 1322-1329.	4.5	71
9	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 4390-4397.	1.6	51
10	Association of <i>BRAF^{V600E}</i> Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid, 2016, 26, 532-542.	4.5	50
11	Preoperative Molecular Markers in Thyroid Nodules. Frontiers in Endocrinology, 2018, 9, 179.	3.5	44
12	Three-Gene Molecular Diagnostic Model for Thyroid Cancer. Thyroid, 2012, 22, 275-284.	4.5	37
13	Human telomerase reverse transcriptase regulation by DNA methylation, transcription factor binding and alternative splicing (Review). International Journal of Oncology, 2016, 49, 2199-2205.	3.3	34
14	Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review. Frontiers in Endocrinology, 2020, 11, 485.	3.5	33
15	Human Telomerase Reverse Transcriptase Gene Expression and the Surgical Management of Suspicious Thyroid Tumors. Clinical Cancer Research, 2004, 10, 5762-5768.	7.0	32
16	Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. Breast Cancer Research and Treatment, 2018, 172, 689-702.	2.5	32
17	<i>TERT</i> promoter mutation determines apoptotic and therapeutic responses of <ibraf< i=""> -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15846-15851.</ibraf<>	7.1	31
18	Thyroid Nodule Diagnostic Markers in the Face of the New NIFTP Category: Time for a Reset?. Thyroid, 2017, 27, 1393-1399.	4.5	25

#	Article	IF	CITATIONS
19	DNA Methylation Markers for Breast Cancer Detection in the Developing World. Clinical Cancer Research, 2019, 25, 6357-6367.	7.0	21
20	Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines. Genes Chromosomes and Cancer, 2019, 58, 530-540.	2.8	21
21	Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?. PLoS ONE, 2014, 9, e105545.	2.5	20
22	Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma. Journal of Proteomics, 2017, 166, 59-67.	2.4	20
23	Telomere Length Is Related to Alternative Splice Patterns of Telomerase in Thyroid Tumors. American Journal of Pathology, 2011, 179, 1415-1424.	3.8	19
24	Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period. Breast Cancer Research and Treatment, 2020, 180, 695-706.	2.5	19
25	Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women's Health Initiative. Thyroid, 2020, 30, 519-530.	4.5	19
26	Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay. Cancers, 2020, 12, 2772.	3.7	18
27	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 3.	5.2	15
28	Characterization of <scp>TERT</scp> and <scp>BRAF</scp> copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study. Genes Chromosomes and Cancer, 2021, 60, 403-409.	2.8	15
29	Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines. Thyroid, 2020, 30, 1470-1481.	4.5	14
30	Measuring DNA Copy Number Variation Using High-Density Methylation Microarrays. Journal of Computational Biology, 2019, 26, 295-304.	1.6	12
31	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. Clinical Epigenetics, 2021, 13, 104.	4.1	10
32	Lower Vitamin D Levels in Surgical Hyperparathyroidism versus Thyroid Patients. American Surgeon, 2014, 80, 505-510.	0.8	6
33	Morphologically compatible mass spectrometric analysis of lipids in cytological specimens. Journal of the American Society of Cytopathology, 2016, 5, 3-8.	0.5	6
34	Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines. Molecular Oncology, 2020, 14 , $2355-2357$.	4.6	5
35	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. Cancer Research Communications, 2022, 2, 391-401.	1.7	5
36	Retrospective analysis of cancer-specific gene expression panel for thyroid fine needle aspiration specimens. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2983-2991.	2.5	1

#	Article	lF	CITATIONS
37	An estimation model for Oncotype DX recurrence score using routine histopathologic variables Journal of Clinical Oncology, 2014, 32, 559-559.	1.6	1